Replies to post #163813 on Biotech Values

[DewDiligence]

Oops—that should read "FDA accepts Eliquis sNDA for primary VTE prevention..."

[DewDiligence]

Eliquis PDUFA date is 8/25/14 for the (supplementary) indications of acute VTE treatment and secondary VTE prevention:

http://finance.yahoo.com/news/fda-accepts-review-eliquis-apixaban-220100204.html

Note: This sNDA is distinct from the pending sNDA in primary VTE prevention, which has a PDUFA date of 3/15/14 (#msg-89831288).

[DewDiligence]

FDA approves Eliquis for VTE prevention following hip/knee replacement:

http://finance.yahoo.com/news/u-fda-approves-eliquis-apixaban-170000729.html

This is Eliquis’ second approved indication in the US; the first (and larger) indication is stroke prevention in AF.

Eliquis was approved in the EU for VTE prevention following hip/knee surgery way back in 2011 (#msg-61114160).